Transduodenal ampullectomy for ampullary tumor
Executive Summary
Transduodenal ampullectomy (TDA) is an underutilized but effective surgical local excision method for ampullary tumors. This briefing document analyzes a retrospective study of 31 patients at Hanyang University Hospital (2004–2019) to evaluate its safety and clinicopathological significance.
Key findings indicate that TDA is a viable alternative to more invasive radical procedures like pancreaticoduodenectomy (PD), particularly for patients with early-stage cancer (Tis, T1) or those who are unsuitable for endoscopic ampullectomy (EA) due to anatomical constraints. While preoperative endoscopic biopsies show significant diagnostic limitations—failing to identify malignancy in 50% of cases later confirmed as cancerous—intraoperative frozen section biopsies provide 100% accuracy in evaluating surgical margins. The study concludes that TDA offers favorable perioperative outcomes, low complication rates, and no mortality within 90 days of surgery.
Context and Indications for Transduodenal Ampullectomy
Ampullary tumors account for approximately 0.5% of gastrointestinal tumors. Excision is the primary treatment because these masses often follow an adenoma-carcinoma sequence and preoperative biopsies frequently yield false negatives.
Current Treatment Landscape
Endoscopic Ampullectomy (EA): The primary choice for benign tumors, though it is often inadequate for large or ulcerative lesions.
Pancreaticoduodenectomy (PD): The standard radical treatment for malignancy, though it carries high morbidity and mortality risks, especially in elderly or frail patients.
Transduodenal Ampullectomy (TDA): A local surgical excision that bridges the gap between EA and PD.
Institution-Specific Indications for TDA
The study outlines three primary criteria for selecting TDA over other methods:
Benign Suspicion with EA Limitation: Cases where endoscopic biopsy does not confirm cancer, but EA is impossible due to lesion size, ulceration, or the patient’s surgical history (e.g., gastric bypass or duodenal deformity).
Early Malignancy in High-Risk Patients: For patients with diagnosed malignancy (Tis or T1 stage) who are poor candidates for PD due to age or general health, or who reject radical surgery.
Absence of Metastasis: Exclusion of patients with jaundice or suspicious lymph node metastasis during preoperative evaluation.
Surgical Methodology and Intraoperative Protocol
The TDA procedure involves a precise sequence of mobilization, resection, and reconstruction.
Operative Technique
Approach: A subcostal incision is made in the supine position, followed by a wide Kocher maneuver to mobilize the duodenum.
Excision: A 4–5 cm duodenostomy is performed. The ampullary mass is tracted and resected using "needle-point" electrocautery in "cutting mode" to ensure clear margins for biopsy.
Reconstruction: The pancreatic and bile ducts are identified and reconstructed using interrupted sutures (5-0 polydioxanone) on the mucosa of the adjacent duodenum. The duodenostomy is closed with double-layer interrupted sutures to prevent stenosis.
The Role of Frozen Biopsy
Intraoperative frozen biopsy is critical for determining the immediate surgical path. If the biopsy reveals positive margins or malignancy in peripancreatic lymph nodes, the procedure is immediately converted to a pancreaticoduodenectomy (PD). In this study, 4 of the 31 patients (12.9%) were converted to PD based on intraoperative findings.
Clinicopathological Analysis and Diagnostic Accuracy
The study highlights a significant disparity between preoperative diagnosis and final pathology, emphasizing the necessity of surgical intervention.
Comparison of Biopsy Results
Key Diagnostic Findings
Preoperative Inaccuracy: Of 18 patients eventually diagnosed with malignancy, only 9 (50%) were correctly identified via preoperative endoscopic biopsy.
Malignancy Rates: Among the 27 patients who completed TDA alone (without conversion to PD), 15 were found to have malignant tumors (55.5%) and 12 had benign tumors (44.4%).
Margin Reliability: Intraoperative frozen biopsies showed a 100% match with final pathology regarding margin status and lymph node metastasis.
Surgical Outcomes and Safety Profile
The study demonstrates that TDA is a safe procedure with manageable perioperative outcomes.
Perioperative Data
Operative Time: Averaged 212.26 minutes across all patients. Malignant cases typically required more time (237.11 minutes) compared to benign cases (172.97 minutes).
Hospital Stay: The average postoperative hospital stay was 14.29 days.
Complications: Severe complications (Clavien-Dindo score III or higher) occurred only in patients converted to PD. No reoperations were required for patients who received only TDA.
Mortality: Zero mortality was recorded within 90 days of the procedure.
Long-term Prognosis
Follow-up: The mean follow-up period was 39.26 months (range 4–137).
Recurrence: In the 15 patients treated with TDA for malignancy, there were zero recurrences during the follow-up period (mean 51.1 months). One benign patient experienced a recurrence of tubular adenoma after 6 months but remained stable for 9 years without additional treatment.
Comparative Literature Review
The study references several other research efforts to contextualize its findings on TDA safety and accuracy:
Conclusions
Transduodenal ampullectomy serves as a reliable and less invasive alternative to radical surgery for highly selective patients. Its primary utility lies in:
Treating benign ampullary tumors that are anatomically unsuitable for endoscopic resection.
Providing a curative option for early-stage ampullary cancer (Tis and T1) in patients with significant comorbidities.
Ensuring oncological safety through the high accuracy of intraoperative frozen biopsies for margin evaluation.
Future development of the field requires large-scale multicenter studies to establish standardized indications and treatment guidelines for TDA.
